Patents Assigned to KODIAK SCIENCES INC.
  • Patent number: 12214044
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: February 4, 2025
    Assignee: KODIAK SCIENCES INC.
    Inventors: Stephen A. Charles, Daniel Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • Patent number: 12071476
    Abstract: The present invention provides antagonizing antibodies that bind to IL-6, fusion proteins thereof with VEGF Trap, and conjugates of either thereof, and methods of using same. The anti-IL-6 antibodies can be used therapeutically alone or in combination with other therapeutics to diseases.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: August 27, 2024
    Assignee: KODIAK SCIENCES INC.
    Inventors: Rachel D. Jacobson, Fernando CorrĂȘa, Hong Liang, Daniel Victor Perlroth
  • Patent number: 11584790
    Abstract: The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 21, 2023
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Wah Yuen To, Hong Liang, Rachel Marie DeVay Jacobson, Fernando CorrĂȘa
  • Patent number: 11155610
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 26, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • Patent number: 11066465
    Abstract: Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 20, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Wah Yuen To, Hong Liang
  • Publication number: 20200262905
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Applicant: KODIAK SCIENCES INC.
    Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • Patent number: 10702608
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: July 7, 2020
    Assignee: KODIAK SCIENCES INC.
    Inventors: Stephen A. Charles, D. Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • Patent number: 10363290
    Abstract: The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: July 30, 2019
    Assignee: KODIAK SCIENCES INC.
    Inventors: D. Victor Perlroth, Stephen A. Charles, Wayne To, Xiaojian Huang, Martin Linsell, Didier Benoit
  • Publication number: 20180244762
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Application
    Filed: November 21, 2017
    Publication date: August 30, 2018
    Applicant: KODIAK SCIENCES INC.
    Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya lshino, William Somers
  • Patent number: 9840553
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: December 12, 2017
    Assignee: KODIAK SCIENCES INC.
    Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didler Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers